SecBot SecBot

SPRY

ARS Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001671858 Biotech & Drug Discovery
$4.03 −0.29 (−6.71%)
Oct 23 4:00 PM ET · prev $4.32
Market cap
$429.6M
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
🔒 Subscribers only
1 year
−55.8%
from $9.11 · Oct 24
30 days
−2.9%
from $4.15
52-week range
$3.93–13.06
−69% from high · low Oct 14
Avg volume 20D
1.54M
shares / day
Short interest
21.19M
≈21.3% of shares · −8.2%
Days to cover
16.1
at average volume
Insider net
-$283.6K
0 buyers · 2 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 1 exit
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 17, 2026
Strongest BEARISH Eric Karas, an officer of ARS Pharmaceuticals, filed a Form 144 notice of intent to sell 100,000 shares of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $283.6K.

  • InstitutionsMIXED

    Q2 2026: 15 added (1 new), 15 trimmed or exited. Largest new: Capital World Investors $22.1M.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −8.2% to 21.19M shares. 16.1 days to cover, ≈21.3% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
1
exit
$22.1M
in new stakes
FundMoveSharesValue
Capital World InvestorsNEW2,754,931$22.1M
MILLENNIUM MANAGEMENT LLCTRIM2,400,937$19.2M
CITADEL ADVISORS LLCTRIM531,063$4.3M
BANK OF AMERICA CORP /DE/ADD463,256$3.7M
GOLDMAN SACHS GROUP INCTRIM380,770$3.0M
RAYMOND JAMES FINANCIAL INCTRIM318,583$2.6M
MORGAN STANLEYTRIM229,100$1.8M
BARCLAYS PLCADD126,261$1.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy5Buy4Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 13, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Jun 25, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
May 28, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$283.6K
sold · 2 insiders
DateInsiderTypeValue
Oct 1, 2026
Casale Donn
President and CEO
AWARD1,036,923 sh
Sep 1, 2026
Smith Margaret Ekins
Chief Commercial Officer
AWARD1,001,738 sh
Jul 1, 2026
Casale Donn
President
AWARD898,456 sh
Jun 24, 2026
Shah Pratik
Director
AWARD30,000 sh
Jun 24, 2026
Islam Saqib
Director
AWARD30,000 sh
Jun 24, 2026
Kelly Michael
Director
AWARD30,000 sh
Jun 24, 2026
Dadoo Rajeev
Director
AWARD30,000 sh
Jun 24, 2026
Thompson Peter A.
Director
AWARD30,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
21,190,047
shares short
-8.2%
vs prior settlement
16.1
days to cover
≈21.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Eric Karas, an officer of ARS Pharmaceuticals, filed a Form 144 notice of intent to sell 100,000 shares of common…
144 — Impact 5/10
Oct 5, 2026 Other
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit
Oct 1, 2026 Insider
Casale Donn was granted 1,036,923 shares
President and CEO
Sep 28, 2026 SEC
A federal district court denied ARS Pharmaceuticals' motion to dismiss a former employee's Title VII gender…
COURT-RULING — Impact 3/10
Sep 28, 2026 Event
Ghani v. ARS Pharmaceuticals
Court ruling (ksd) — Docket: 2:25-cv-02282
Sep 16, 2026 SEC
The court denied ARS Pharmaceuticals' objection to a magistrate order granting the plaintiff leave to file a third…
COURT-RULING — Impact 2/10
Sep 1, 2026 Insider
Smith Margaret Ekins was granted 1,001,738 shares
Chief Commercial Officer
Jul 1, 2026 Insider
Casale Donn was granted 898,456 shares
President
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 5, 2026
Press release
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or…
Oct 5, 2026
Press release
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Oct. 5, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of…
Oct 2, 2026
Press release
ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals…
Sep 29, 2026
Press release
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS…
Sep 28, 2026
Press release
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or…

SecBot reports

11 filings · 2 press releases · 0 bullish · 2 bearish · 9 neutral
All SPRY filing & press-release reports (13)